Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (Matrix and Platinum Science) trial

Cameron McDougall, S. Claiborne Johnston, A. Gholkar, S. L. Barnwell, J. C. Vazquez Suarez, J. Massó Romero, J. C. Chaloupka, A. Bonafe, A. K. Wakhloo, D. Tampieri, C. F. Dowd, A. J. Fox, S. J. Imm, K. Carroll, A. S. Turk

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE: The ability of polymer-modified coils to promote stable aneurysm occlusion after endovascular treatment is not well-documented. Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited. This trial compares the effectiveness of Matrix2 polyglycolic/polylactic acid biopolymer-modified coils with bare metal coils and correlates the angiographic findings with clinical failure (ie, target aneurysm recurrence), a composite end point that includes any incident of posttreatment aneurysm rupture, retreatment, or unexplained death. MATERIALSANDMETHODS: This was a multicenter randomized noninferiority trial with blinded end point adjudication.Weenrolled 626 patients, divided between Matrix2 and bare metal coil groups. The primary outcome was target aneurysm recurrence at 12 ± 3 months. RESULTS: At 455 days, at least 1 target aneurysm recurrence event had occurred in 14.6% of patients treated with bare metal coils and 13.3% of Matrix2 (P=.76, log-rank test) patients; 92.8% of target aneurysm recurrence events were re-interventions for aneurysms that had not bled after treatment, and 5.8% of target aneurysm recurrence events resulted from hemorrhage or rehemorrhage, with or without retreatment. Symptomatic re-intervention occurred in only 4 (0.6%) patients. At 455 days, 95.8% of patients with unruptured aneurysms and 90.4% of those with ruptured aneurysms were independent (mRS ≤ 2). Target aneurysm recurrence was associated with incomplete initial angiographic aneurysm obliteration, presentation with rupture, and a larger aneurysmal dome and neck size. CONCLUSIONS: Tested Matrix2 coils were not inferior to bare metal coils. Endovascular coiling of intracranial aneurysms was safe, and the rate of technical success was high. Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements.

Original languageEnglish (US)
Pages (from-to)935-942
Number of pages8
JournalAmerican Journal of Neuroradiology
Volume39
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Intracranial Aneurysm
Platinum
Aneurysm
Recurrence
Therapeutics
Metals
Retreatment
Rupture
Polyglycolic Acid
Ruptured Aneurysm
Biopolymers
Treatment Failure
Polymers
Neck
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

McDougall, C., Claiborne Johnston, S., Gholkar, A., Barnwell, S. L., Vazquez Suarez, J. C., Massó Romero, J., ... Turk, A. S. (2014). Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (Matrix and Platinum Science) trial. American Journal of Neuroradiology, 39(5), 935-942. https://doi.org/10.3174/ajnr.A3857

Bioactive versus bare platinum coils in the treatment of intracranial aneurysms : The MAPS (Matrix and Platinum Science) trial. / McDougall, Cameron; Claiborne Johnston, S.; Gholkar, A.; Barnwell, S. L.; Vazquez Suarez, J. C.; Massó Romero, J.; Chaloupka, J. C.; Bonafe, A.; Wakhloo, A. K.; Tampieri, D.; Dowd, C. F.; Fox, A. J.; Imm, S. J.; Carroll, K.; Turk, A. S.

In: American Journal of Neuroradiology, Vol. 39, No. 5, 01.01.2014, p. 935-942.

Research output: Contribution to journalArticle

McDougall, C, Claiborne Johnston, S, Gholkar, A, Barnwell, SL, Vazquez Suarez, JC, Massó Romero, J, Chaloupka, JC, Bonafe, A, Wakhloo, AK, Tampieri, D, Dowd, CF, Fox, AJ, Imm, SJ, Carroll, K & Turk, AS 2014, 'Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (Matrix and Platinum Science) trial', American Journal of Neuroradiology, vol. 39, no. 5, pp. 935-942. https://doi.org/10.3174/ajnr.A3857
McDougall, Cameron ; Claiborne Johnston, S. ; Gholkar, A. ; Barnwell, S. L. ; Vazquez Suarez, J. C. ; Massó Romero, J. ; Chaloupka, J. C. ; Bonafe, A. ; Wakhloo, A. K. ; Tampieri, D. ; Dowd, C. F. ; Fox, A. J. ; Imm, S. J. ; Carroll, K. ; Turk, A. S. / Bioactive versus bare platinum coils in the treatment of intracranial aneurysms : The MAPS (Matrix and Platinum Science) trial. In: American Journal of Neuroradiology. 2014 ; Vol. 39, No. 5. pp. 935-942.
@article{46ba7e91e9da420f9982360afeafe83f,
title = "Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (Matrix and Platinum Science) trial",
abstract = "BACKGROUND AND PURPOSE: The ability of polymer-modified coils to promote stable aneurysm occlusion after endovascular treatment is not well-documented. Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited. This trial compares the effectiveness of Matrix2 polyglycolic/polylactic acid biopolymer-modified coils with bare metal coils and correlates the angiographic findings with clinical failure (ie, target aneurysm recurrence), a composite end point that includes any incident of posttreatment aneurysm rupture, retreatment, or unexplained death. MATERIALSANDMETHODS: This was a multicenter randomized noninferiority trial with blinded end point adjudication.Weenrolled 626 patients, divided between Matrix2 and bare metal coil groups. The primary outcome was target aneurysm recurrence at 12 ± 3 months. RESULTS: At 455 days, at least 1 target aneurysm recurrence event had occurred in 14.6{\%} of patients treated with bare metal coils and 13.3{\%} of Matrix2 (P=.76, log-rank test) patients; 92.8{\%} of target aneurysm recurrence events were re-interventions for aneurysms that had not bled after treatment, and 5.8{\%} of target aneurysm recurrence events resulted from hemorrhage or rehemorrhage, with or without retreatment. Symptomatic re-intervention occurred in only 4 (0.6{\%}) patients. At 455 days, 95.8{\%} of patients with unruptured aneurysms and 90.4{\%} of those with ruptured aneurysms were independent (mRS ≤ 2). Target aneurysm recurrence was associated with incomplete initial angiographic aneurysm obliteration, presentation with rupture, and a larger aneurysmal dome and neck size. CONCLUSIONS: Tested Matrix2 coils were not inferior to bare metal coils. Endovascular coiling of intracranial aneurysms was safe, and the rate of technical success was high. Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements.",
author = "Cameron McDougall and {Claiborne Johnston}, S. and A. Gholkar and Barnwell, {S. L.} and {Vazquez Suarez}, {J. C.} and {Mass{\'o} Romero}, J. and Chaloupka, {J. C.} and A. Bonafe and Wakhloo, {A. K.} and D. Tampieri and Dowd, {C. F.} and Fox, {A. J.} and Imm, {S. J.} and K. Carroll and Turk, {A. S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.3174/ajnr.A3857",
language = "English (US)",
volume = "39",
pages = "935--942",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "5",

}

TY - JOUR

T1 - Bioactive versus bare platinum coils in the treatment of intracranial aneurysms

T2 - The MAPS (Matrix and Platinum Science) trial

AU - McDougall, Cameron

AU - Claiborne Johnston, S.

AU - Gholkar, A.

AU - Barnwell, S. L.

AU - Vazquez Suarez, J. C.

AU - Massó Romero, J.

AU - Chaloupka, J. C.

AU - Bonafe, A.

AU - Wakhloo, A. K.

AU - Tampieri, D.

AU - Dowd, C. F.

AU - Fox, A. J.

AU - Imm, S. J.

AU - Carroll, K.

AU - Turk, A. S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BACKGROUND AND PURPOSE: The ability of polymer-modified coils to promote stable aneurysm occlusion after endovascular treatment is not well-documented. Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited. This trial compares the effectiveness of Matrix2 polyglycolic/polylactic acid biopolymer-modified coils with bare metal coils and correlates the angiographic findings with clinical failure (ie, target aneurysm recurrence), a composite end point that includes any incident of posttreatment aneurysm rupture, retreatment, or unexplained death. MATERIALSANDMETHODS: This was a multicenter randomized noninferiority trial with blinded end point adjudication.Weenrolled 626 patients, divided between Matrix2 and bare metal coil groups. The primary outcome was target aneurysm recurrence at 12 ± 3 months. RESULTS: At 455 days, at least 1 target aneurysm recurrence event had occurred in 14.6% of patients treated with bare metal coils and 13.3% of Matrix2 (P=.76, log-rank test) patients; 92.8% of target aneurysm recurrence events were re-interventions for aneurysms that had not bled after treatment, and 5.8% of target aneurysm recurrence events resulted from hemorrhage or rehemorrhage, with or without retreatment. Symptomatic re-intervention occurred in only 4 (0.6%) patients. At 455 days, 95.8% of patients with unruptured aneurysms and 90.4% of those with ruptured aneurysms were independent (mRS ≤ 2). Target aneurysm recurrence was associated with incomplete initial angiographic aneurysm obliteration, presentation with rupture, and a larger aneurysmal dome and neck size. CONCLUSIONS: Tested Matrix2 coils were not inferior to bare metal coils. Endovascular coiling of intracranial aneurysms was safe, and the rate of technical success was high. Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements.

AB - BACKGROUND AND PURPOSE: The ability of polymer-modified coils to promote stable aneurysm occlusion after endovascular treatment is not well-documented. Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited. This trial compares the effectiveness of Matrix2 polyglycolic/polylactic acid biopolymer-modified coils with bare metal coils and correlates the angiographic findings with clinical failure (ie, target aneurysm recurrence), a composite end point that includes any incident of posttreatment aneurysm rupture, retreatment, or unexplained death. MATERIALSANDMETHODS: This was a multicenter randomized noninferiority trial with blinded end point adjudication.Weenrolled 626 patients, divided between Matrix2 and bare metal coil groups. The primary outcome was target aneurysm recurrence at 12 ± 3 months. RESULTS: At 455 days, at least 1 target aneurysm recurrence event had occurred in 14.6% of patients treated with bare metal coils and 13.3% of Matrix2 (P=.76, log-rank test) patients; 92.8% of target aneurysm recurrence events were re-interventions for aneurysms that had not bled after treatment, and 5.8% of target aneurysm recurrence events resulted from hemorrhage or rehemorrhage, with or without retreatment. Symptomatic re-intervention occurred in only 4 (0.6%) patients. At 455 days, 95.8% of patients with unruptured aneurysms and 90.4% of those with ruptured aneurysms were independent (mRS ≤ 2). Target aneurysm recurrence was associated with incomplete initial angiographic aneurysm obliteration, presentation with rupture, and a larger aneurysmal dome and neck size. CONCLUSIONS: Tested Matrix2 coils were not inferior to bare metal coils. Endovascular coiling of intracranial aneurysms was safe, and the rate of technical success was high. Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements.

UR - http://www.scopus.com/inward/record.url?scp=84901004691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901004691&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A3857

DO - 10.3174/ajnr.A3857

M3 - Article

C2 - 24481333

AN - SCOPUS:84901004691

VL - 39

SP - 935

EP - 942

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 5

ER -